Intravitreal triamcinolone acetonide: potential complications

References

• Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman & Gilman’s The pharmacological basis of therapeutics. Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A (Eds). McGraw-Hill, NY, USA 1459–1485 (1996).
   Google Scholar
• Peyman GA, Moshfeghi DM. Intravitreal triamcinolone acetonide. Retina24(3), 488–490 (2004).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog. Retin. Eye Res.24(5), 587–611 (2005).
   PubMed Web of Science ®Google Scholar
• Jager RD, Aiello LP, Patel SC, Cunningham ET, Jr. Risks of intravitreous injection: a comprehensive review. Retina24(5), 676–698 (2004).
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Szurman P, Bartz-Schmidt KU. Nebenwirkungen und Komplikationen der intravitrealen Triamcinolonacetonid. Therapie. Ophthalmologe.101(2), 121–128 (2004).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology112(4), 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Aiello LP, Brucker AJ, Chang S et al. Evolving guidelines for intravitreous injections. Retina, 24(5 Suppl.) S3–S19 (2004).
   Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351(27), 2805–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Ohm J. Über die behandlung der netzhautablösung durch operative entleerung der subretinalen flüssigkeit und einspritzung von luft in den glaskörper. Albrecht. von Graefes Arch. Ophthalmol.79, 442–450 (1911).
   Google Scholar
• Baum J, Peyman GA, Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv. Ophthalmol.26(4), 204–206 (1982).
   PubMed Web of Science ®Google Scholar
• FDA, Food and Frug Administration. Vitravene® Injection (fomivirsen sodium intravitreal injectable) Approval Letter. US Food and Drug Administration (1998)
   Google Scholar
• Blankenship GW. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch. Clin. Exp. Ophthalmol.229(1), 62–65 (1991).
   PubMed Web of Science ®Google Scholar
• Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. NZ J. Ophthalmol.23(4), 293–298 (1995).
   PubMedGoogle Scholar
• Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch. Ophthalmol.115(9), 1152–1156 (1997).
   PubMed Web of Science ®Google Scholar
• Hassan AS, Johnson MW, Schneiderman TE et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology106(10), 1900–1906 (1999).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol.140(4), 573–584 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina26(4), 383–390 (2006).
   PubMed Web of Science ®Google Scholar
• Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch. Ophthalmol.92(2), 149–154 (1974).
   PubMed Web of Science ®Google Scholar
• Giles CL. Bulbar perforation during periocular injection of corticosteroids. Am. J. Ophthalmol.77(4), 438–441 (1974).
   PubMedGoogle Scholar
• Schlaegel TJ, Wilson F. Accidental injection of depot corticosteroids. Trans. Am. Acad. Ophthalmol. Otolaryngol.78, 847–855 (1974).
   Google Scholar
• McLean EB. Inadvertent injection of corticosteroid into the choroidal vasculature. Am. J. Ophthalmol.80(5), 835–837 (1975).
   PubMed Web of Science ®Google Scholar
• Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans. Am. Ophthalmol. Soc.77, 171–180 (1979).
   PubMedGoogle Scholar
• Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am. J. Ophthalmol.89(1), 131–136 (1980).
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch. Ophthalmol.103(5), 708–711 (1985).
   PubMed Web of Science ®Google Scholar
• McCuen BW 2nd, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am. J. Ophthalmol.91(6), 785–788 (1981).
   PubMed Web of Science ®Google Scholar
• Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am. J. Ophthalmol.101(2), 190–195 (1986).
   PubMed Web of Science ®Google Scholar
• Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol.110(2), 259–266 (1992).
   PubMed Web of Science ®Google Scholar
• Michaud C. L’Acetonide de triamcinolone sous-conjonctival en chirurgie oculaire. Union Med. Can., 98(3), 447–449 (1969).
   PubMedGoogle Scholar
• Nozik RA. Periocular injection of steroids. Trans. Am. Acad. Ophthalmol. Otolaryngol.76(3), 695–705 (1972).
   PubMedGoogle Scholar
• Pizzarello LD, Jakobiec FA, Hofeldt AJ, Podolsky MM, Silvers DN. Intralesional corticosteroid therapy of chalazia. Am. J. Ophthalmol.85(6), 818–821 (1978).
   PubMed Web of Science ®Google Scholar
• Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am. J. Ophthalmol.93(4), 415–417 (1982).
   PubMed Web of Science ®Google Scholar
• Brooks HL Jr, Caballero S Jr, Newell CK et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch. Ophthalmol.122(12), 1801–1807 (2004).
   PubMed Web of Science ®Google Scholar
• Tong JP, Lam DS, Chan WM et al. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol. Vis.12, 1490–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson CA, Berkowitz BA, Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch. Ophthalmol.110(8), 1155–1159 (1992).
   PubMed Web of Science ®Google Scholar
• Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina20(3), 244–250 (2000).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Luo W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch. Ophthalmol.121(5), 667–673 (2003).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology110(8), 1517–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br. J. Ophthalmol.88(3), 344–347 (2004).
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology113(1), 14–22 (2006).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am. J. Ophthalmol.131(4), 468–471 (2001).
   PubMed Web of Science ®Google Scholar
• Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can. J. Ophthalmol.40(5), 598–604 (2005).
   PubMed Web of Science ®Google Scholar
• Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br. J. Ophthalmol.86(2), 247–248 (2002).
   PubMed Web of Science ®Google Scholar
• Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S. Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch. Clin. Exp. Ophthalmol.244(12), 1601–1606 (2006).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am. J. Ophthalmol.139(6), 972–982 (2005).
   PubMed Web of Science ®Google Scholar
• Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am. J. Ophthalmol.141(5), 876–883 (2006).
   PubMed Web of Science ®Google Scholar
• Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina23(1), 113–116 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez JA. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch. Opthalmol.121(11), 1658–1659 (2003).
   PubMedGoogle Scholar
• Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J. Glaucoma10(4), 284–287 (2001).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring RF. Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmol. Scand.81(5), 540–541 (2003).
   PubMedGoogle Scholar
• Benhamou N, Massin P, Haouchine B et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am. J. Ophthalmol.135(2), 246–249 (2003).
   PubMed Web of Science ®Google Scholar
• Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J. Cataract. Refract. Surg.29(1), 27–33 (2003).
   PubMed Web of Science ®Google Scholar
• Koutsandrea C, Moschos MM, Brouzas D et al. Intraocular triamcinolone acetonide for pseudophakic cystoid macular edema: optical coherence tomography and multifocal electroretinography study. Retina27(2), 159–164 (2007).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am. J. Ophthalmol.132(3), 425–427 (2001).
   PubMed Web of Science ®Google Scholar
• Martidis A, Duker JS, Greenberg PB et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology109(5), 920–927 (2002).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology113(9), 1533–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Rosenfeld PJ, Puliafito CA et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina26(8), 889–895 (2006).
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Spalton DJ, Stanford MR et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology108(4), 765–772 (2001).
   PubMed Web of Science ®Google Scholar
• Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology112(11), 1916 (2005).
   PubMed Web of Science ®Google Scholar
• Morrison VL, Kozak I, LaBree LD et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology114(2), 334–339 (2007).
   PubMed Web of Science ®Google Scholar
• Sutter FK, Gillies MC. Intravitreal triamcinolone for radiation-induced macular edema. Arch. Opthalmol.121(10), 1491–1493 (2003).
   PubMed Web of Science ®Google Scholar
• Shields CL, Demirci H, Dai V et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina25(7), 868–874 (2005).
   PubMed Web of Science ®Google Scholar
• Saraiva VS, Sallum JM, Farah ME. Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg. Lasers Imaging34(5), 398–400 (2003).
   PubMedGoogle Scholar
• Vasconcelos-Santos D, Magalhães E, Nehemy M. Macular edema associated to gyrate atrophy managed with intravitreal triamcinolone – case report. Arq. Bras. Oftalmol.70(5), 858–861(2007).
   PubMedGoogle Scholar
• Scott IU, Flynn HW, Jr., Rosenfeld PJ. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am. J. Ophthalmol.136(4), 737–739 (2003).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br. J. Ophthalmol.84(9), 1064–1067 (2000).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Graefes Arch. Clin. Exp. Ophthalmol.239(6), 464–465 (2001).
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intravitreal triamcinolone for treatment of chronic focal immunological corneal graft reaction. Graefes Arch. Clin. Exp. Ophthalmol.241(9), 779–780 (2003).
   PubMed Web of Science ®Google Scholar
• Rakic JM, Zelinkova M, Comhaire-Poutchinian Y, Galand A, Duchateau E. Traitement des oedemes maculaires Graves par injection intravitreenne de corticosteroides. Bull. Soc. Belge. Ophtalmol.(288), 43–48 (2003).
   PubMedGoogle Scholar
• Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. Eur. J. Ophthalmol.13(6), 575–576 (2003).
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Miyazaki M, Hisatomi T et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch. Clin. Exp. Ophthalmol.240(6), 423–429 (2002).
   PubMed Web of Science ®Google Scholar
• Burk SE, Da Mata AP, Snyder ME et al. Visualizing vitreous using Kenalog suspension. J. Cataract. Refract. Surg.29(4), 645–651 (2003).
   PubMed Web of Science ®Google Scholar
• Kimura H, Kuroda S, Nagata M. Triamcinolone acetonide-assisted peeling of the internal limiting membrane. Am. J. Ophthalmol.137(1), 172–173 (2004).
   PubMed Web of Science ®Google Scholar
• Shah GK, Rosenblatt BJ, Blinder KJ, Grand MG, Smith M. Triamcinolone-assisted internal limiting membrane peeling. Retina25(8), 972–975 (2005).
   PubMed Web of Science ®Google Scholar
• Erol N, Topbas S, Sahin A. Retinal break following an intravitreal triamcinolone acetonide injection. Int. Ophthalmol.26(4–5), 163–165 (2005).
   PubMedGoogle Scholar
• Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye21(3), 317–320 (2007).
   PubMed Web of Science ®Google Scholar
• Glacet-Bernard A, Voigt M, Coscas G, Soubrane G. Full-thickness macular hole following intravitreal injection of triamcinolone acetonide in central retinal vein occlusion. Retinal Cases and Brief Reports1(2), 62–64 (2007).
   Google Scholar
• Perry HT, Cohn BT, JS NA. Accidental intraocular injection with Dermojet syringe. Arch. Dermatol113(8), 1131 (1977).
   PubMedGoogle Scholar
• Zheng Y, Sun N, Xiong Q, Wang X, Quan Y. Triamcinolone-assisted pars plana vitrectomy for retinal disease. Yan Ke Xue Bao21(3), 142–146 (2005).
   Google Scholar
• Bucher RS, Hall E, Reed DM et al. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch. Dermatol.123(5), 649–653 (2005).
   Google Scholar
• Chen SD, Mohammed Q, Bowling B, Patel CK. Vitreous wick syndrome – a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am. J. Ophthalmol.137(6), 1159–1160 (2004).
   PubMed Web of Science ®Google Scholar
• Westfall AC, Osborn A, Kuhl D et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch. Opthalmol.123(8), 1075–1077 (2005).
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Scott IU et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol.136(5), 791–796 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson ML, Tennant MT, Sivalingam A et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina23(5), 686–691 (2003).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am. J. Ophthalmol.141(3), 579–580 (2006).
   PubMed Web of Science ®Google Scholar
• Rajak SN, Dubois VD, Mokete B, Casswell AG. The inadvertent administration of intralenticular triamcinolone. Eye21(3), 426–427 (2007).
   PubMed Web of Science ®Google Scholar
• Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone’s vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch. Clin. Exp. Ophthalmol.245(6), 817–824 (2007).
   PubMed Web of Science ®Google Scholar
• Morrison VL, Koh HJ, Cheng L et al. Intravitreal toxicity of the kenalog vehicle (benzyl alcohol) in rabbits. Retina26(3), 339–344 (2006).
   PubMed Web of Science ®Google Scholar
• Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch. Clin. Exp. Ophthalmol.244(9), 1152–1159 (2006).
   PubMed Web of Science ®Google Scholar
• Shaikh S, Ho S, Engelmann LA, Klemann SW. Cell viability effects of triamcinolone acetonide and preservative vehicle formulations. Br. J. Ophthalmol.90(2), 233–236 (2006).
   PubMed Web of Science ®Google Scholar
• Szurman P, Kaczmarek R, Spitzer MS et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp. Eye Res.83(3), 584–592 (2006).
   PubMed Web of Science ®Google Scholar
• Yu SY, Damico FM, Viola F, D’Amico DJ, Young LH. Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina26(5), 531–536 (2006).
   PubMed Web of Science ®Google Scholar
• Roth DB, Chieh J, Spirn MJ et al. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch. Opthalmol.121(9), 1279–1282 (2003).
   PubMed Web of Science ®Google Scholar
• Magalhaes E, Nehemy P, Santos DV, Fujji G, Nehemy MB. Avaliação clínica e incidência de endoftalmite infecciosa e não-infecciosa após injeção intravítrea de acetonida de triancinolona. Arq. Bras. Oftalmol.69(6), 791–794 (2006).
   PubMedGoogle Scholar
• Maia M, Farah ME, Belfort Neto RN et al. Effects of intravitreal triamcinolone acetonide injection with and without Preservatives. Br. J. Ophthalmol. (2007).
   Google Scholar
• Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can. J. Ophthalmol.40(1), 63–68 (2005).
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4mg of triamcinolone acetonide: incidence and risk factors. Retina (2007).[In Press].
   Google Scholar
• Rhee DJ, Peck RE, Belmont J et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br. J. Ophthalmol.90(8), 999–1003 (2006).
   PubMed Web of Science ®Google Scholar
• Kivilcim M, Peyman GA, El-Dessouky ES et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic. Surg. Lasers31(6), 474–478 (2000).
   PubMedGoogle Scholar
• Dierks D, Lei B, Zhang K, Hainsworth DP. Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch. Opthalmol.123(11), 1563–1569 (2005).
   PubMedGoogle Scholar
• Albini TA, Abd-El-Barr MM, Carvounis PE et al. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest. Ophthalmol. Vis. Sci.48(1), 390–395 (2007).
   PubMed Web of Science ®Google Scholar
• Lang Y, Leibu R, Shoham N, Miller B, Perlman I. Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology114(4), 724–731 (2007).
   PubMed Web of Science ®Google Scholar
• Kumagai K. Introduction of a new method for the preparation of triamcinolone acetonide solution as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina23(6), 881–882 (2003).
   PubMed Web of Science ®Google Scholar
• Nishimura A, Kobayashi A, Segawa Y et al. Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina23(6), 777–779 (2003).
   PubMed Web of Science ®Google Scholar
• Hernaez-Ortega MC, Soto-Pedre E. A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg. Lasers Imaging35(4), 350–351 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Arumi J, Boixadera A, Giralt J et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br. J. Ophthalmol.89(9), 1112–1114 (2005).
   PubMed Web of Science ®Google Scholar
• Kim H, Csaky KG, Gravlin L et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina26(5), 523–530 (2006).
   PubMed Web of Science ®Google Scholar
• Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am. J. Ophthalmol.140(6), 1141–1143 (2005).
   PubMed Web of Science ®Google Scholar
• Dalessandro L, Bottaro E. Reactivation of CMV retinitis after treatment with subtenon corticosteroids for immune recovery uveitis in a patient with AIDS. Scand. J. Infect. Dis.34(10), 780–782 (2002).
   PubMedGoogle Scholar
• Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am. J. Ophthalmol.143(2), 334–335 (2007).
   PubMed Web of Science ®Google Scholar
• Bacsal K, Chee SP. Ocular toxoplasmosis. Ophthalmology114(3), 616 (2007).
   PubMed Web of Science ®Google Scholar
• Nobrega MJ, Rosa EL. Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: a case report. Arq. Bras. Oftalmol.70(1), 157–160 (2007).
   PubMedGoogle Scholar
• Erol N, Topbas S. Acute syphilitic posterior placoid chorioretinitis after an intravitreal triamcinolone acetonide injection. Acta Ophthalmol. Scand.84(3), 435 (2006).
   PubMedGoogle Scholar
• Toh T, Borthwick JH. Acute retinal necrosis post intravitreal injection of triamcinolone acetonide. Clin. Experiment Ophthalmol.34(4), 380–382 (2006).
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Prasad S. Conjunctival necrosis following intravitreal injection of triamcinolone acetonide. Cornea24(8), 1027–1028 (2005).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal J, Agrawal TP. Conjunctival ulceration following triamcinolone injection. Am. J. Ophthalmol.136(3), 539–540 (2003).
   PubMed Web of Science ®Google Scholar
• Chen SD, Lochhead J, McDonald B, Patel CK. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br. J. Ophthalmol.88(6), 843–844 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma MC, Lai WW, Shapiro MJ. Pseudohypopyon following intravitreal triamcinolone acetonide injection. Cornea23(4), 398–399 (2004).
   PubMed Web of Science ®Google Scholar
• Torqueti-Costa L, Vasconcelos-Santos DV, Magalhaes EP et al. Pseudoendoftalmite associada à injeção intravítrea de triancinolona. Rev. Bras. Oftalmol.64(1), 37–41 (2005).
   Google Scholar
• Lee JW, Iwatsuru M, Nishigori H. Glucocorticoid-induced cataract of developing chick embryo as a screening model for anticataract agents. J. Ocul. Pharmacol. Ther.11(4), 533–541 (1995).
   PubMed Web of Science ®Google Scholar
• Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspective from in vitro and lens culture studies. Exp. Eye Res.65(4), 507–516 (1997).
   PubMed Web of Science ®Google Scholar
• Pescosolido N, Miccheli A, Manetti C et al. Metabolic changes in rabbit lens induced by treatment with dexamethasone. Ophthalmic. Res.33(2), 68–74 (2001).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring R, Vossmerbauemer U, Kamppeter B. Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur. J. Ophthalmol.15(4), 462–464 (2005).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Billson FA et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch. Opthalmol.122(3), 336–340 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol.141(4), 629–637 (2006).
   PubMed Web of Science ®Google Scholar
• Gillies MC, Kuzniarz M, Craig J et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology112(1), 139–143 (2005).
   PubMed Web of Science ®Google Scholar
• Cekic O, Chang S, Tseng JJ et al. Cataract progression after intravitreal triamcinolone injection. Am. J. Ophthalmol.139(6), 993–998 (2005).
   PubMed Web of Science ®Google Scholar
• Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye21(3), 321–323 (2007).
   PubMed Web of Science ®Google Scholar
• McLean J, Gordon DM, Koteen H. Clinical experiences with ACTH and cortisone in ocular diseases. Trans. Am. Acad. Ophthalmol. Otolaryngol.55, 565–572 (1951).
   PubMedGoogle Scholar
• Armaly MF. Effect of Corticosteroids on Intraocular Pressure and Fluid Dynamics. I. the Effect of Dexamethasone in the Normal Eye. Arch. Opthalmol.70, 482–491 (1963).
   PubMed Web of Science ®Google Scholar
• Becker B, Mills DW. Corticosteroids and Intraocular Pressure. Arch. Opthalmol.70, 500–507 (1963).
   PubMed Web of Science ®Google Scholar
• Francois J. Cortisone et tension oculaire. Ann. Ocul. (Paris)187(9), 805–816 (1954).
   PubMedGoogle Scholar
• Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog. Retin. Eye Res.18(5), 629–667 (1999).
   PubMed Web of Science ®Google Scholar
• Cantrill HL, Palmberg PF, Zink HA et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am. J. Ophthalmol.79(6), 1012–1017 (1975).
   PubMed Web of Science ®Google Scholar
• Clark A. Steroids, ocular hypertension and glaucoma. J. Glaucoma4, 354–369 (1995).
   PubMedGoogle Scholar
• Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest. Ophthalmol.4, 187–197 (1965).
   PubMedGoogle Scholar
• Becker B. Intraocular pressure response to topical corticosteroids. Invest. Ophthalmol.4, 198–205 (1965).
   PubMedGoogle Scholar
• Bartlett JD, Woolley TW, Adams CM. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J. Ocul. Pharmacol.9(1), 35–45 (1993).
   PubMedGoogle Scholar
• Bui CM, Chen H, Shyr Y, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J. Allergy Clin. Immunol.116(5), 1042–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Kubota T, Okabe H, Hisatomi T et al. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J. Glaucoma15(2), 117–119 (2006).
   PubMed Web of Science ®Google Scholar
• Singh IP, Ahmad SI, Yeh D et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol.138(2), 286–287 (2004).
   PubMed Web of Science ®Google Scholar
• Vedantham V. Intraocular pressure rise after intravitreal triamcinolone. Am. J. Ophthalmol.139(3), 575 (2005).
   PubMedGoogle Scholar
• Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust. NZ J. Ophthalmol.27(6), 431–432 (1999).
   PubMedGoogle Scholar
• Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg. Lasers Imaging34(5), 386–390 (2003).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol.87(1), 24–27 (2003).
   PubMed Web of Science ®Google Scholar
• Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am. J. Ophthalmol.138(5), 740–743 (2004).
   PubMed Web of Science ®Google Scholar
• Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J. Ophthalmol.19(2), 122–127 (2005).
   PubMedGoogle Scholar
• Avci R, Kaderli B, Akalp FD. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clin. Experiment Ophthalmol.34(1), 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Santos D, Magalhães E, Nehemy M. IVTA and glaucoma: Brazil report. 13.09.2006, e-letter in Br. J. Ophthalmol. (2006).
   Google Scholar
• Meyer CH, Mennel S, Schmidt JC. Intravitreal triamcinolone acetonide may increase the intraocular pressure even in vitrectomized eyes after more than 3 months. Am. J. Ophthalmol.140(4), 766–767 (2005).
   PubMedGoogle Scholar
• Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am. J. Ophthalmol.137(3), 560–562 (2004).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am. J. Ophthalmol.138(1), 158–160 (2004).
   PubMed Web of Science ®Google Scholar
• Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br. J. Ophthalmol.90(6), 705–708 (2006).
   PubMed Web of Science ®Google Scholar
• Mason JO, 3rd, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina24(6), 900–904 (2004).
   PubMed Web of Science ®Google Scholar
• Beer PM, Bakri SJ, Singh RJ et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology110(4), 681–686 (2003).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agrawal J, Agrawal TP. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol.138(4), 679–680 (2004).
   PubMed Web of Science ®Google Scholar
• Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch. Opthalmol.124(1), 133–134 (2006).
   PubMed Web of Science ®Google Scholar
• Ricci F, Missiroli F, Parravano M. Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. Eur. J. Ophthalmol.16(5), 756–757 (2006).
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Santos DV, Torqueti-Costa L, Magalhaes EP et al. Efeito da triancinolona intravítrea na pressão intra-ocular. Rev. Bras. Oftalmol.64(1), 32–36 (2005).
   Google Scholar